Jideytro is a drug owned by Nuvalent Inc. It is protected by 4 US drug patents filed in 2026 out of which none have expired yet. Jideytro's patents will be open to challenges from 22 July, 2030. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 30, 2042. Details of Jideytro's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US12043626 | Solid Forms, Pharmaceutical Compositions And Preparation Of Heteroaromatic Macrocyclic Ether Compounds |
Sep, 2042
(16 years from now) | Active |
| US11542278 | NA |
May, 2041
(14 years from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12630560 | Solid Forms, Pharmaceutical Compositions And Preparation Of Heteroaromatic Macrocyclic Ether Compounds |
Sep, 2042
(16 years from now) | Active |
| US12054498 | Heteroaromatic Macrocyclic Ether Chemotherapeutic Agents |
May, 2041
(14 years from now) | Active |
FDA has granted several exclusivities to Jideytro. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Jideytro, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Jideytro.
Exclusivity Information
Jideytro holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2031. Details of Jideytro's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 22, 2031 |
US patents provide insights into the exclusivity only within the United States, but
Jideytro is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Jideytro's family patents as well as insights into
ongoing legal events
on those patents.
Jideytro's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Jideytro's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Sep 30, 2042 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Jideytro Generics:
There are no approved generic versions for Jideytro as of now.
About Jideytro
Jideytro is a drug owned by Nuvalent Inc. Jideytro uses Zidesamtinib as an active ingredient. Jideytro was launched by Nuvalent in 2026.
Approval Date:
Jideytro was approved by FDA for market use on 22 July, 2026.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Jideytro is 22 July, 2026, its NCE-1 date is estimated to be 22 July, 2030.
Active Ingredient:
Jideytro uses Zidesamtinib as the active ingredient. Check out other Drugs and Companies using Zidesamtinib ingredient
Dosage:
Jideytro is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 100MG | TABLET | Prescription | ORAL |
| 25MG | TABLET | Prescription | ORAL |